The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On May 4, 2026, after market hours, GeneDx released its first quarter 2026 financial results, revealing earnings per share of -$0.28, and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint.

GeneDx revealed it had “lower-than-expected blended average reimbursement rate for exome and genome” and “softer-than-expected performance from [its] noncore business lines” including Fabric Genomics.

The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, “primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.”

On this news, GeneDx’s stock price fell as much as 50% during intraday trading on May 5, 2026, thereby injuring investors.